Showing results (81-90 of 178) with videos related to

Sort By:
Pageof 18
Cancer Discovery|March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
Cancer Letters|September 26, 2015
F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancerBenoît Thibault, Emily Clement, Grégoire Zorza, et al.
Clinical Colorectal Cancer|August 2, 2011
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyJaafar Bennouna, Christophe Borg, Jean-Pierre Delord, et al.
Investigational New Drugs|November 13, 2012
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumorsThierry Lesimple, Julien Edeline, Timothy J Carrothers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
Investigational New Drugs|November 10, 2018
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumorsElena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyHyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid TumorsJeremy Lewin, Jean-Charles Soria, Anastasios Stathis, et al.
Pageof 18